The largest database of trusted experimental protocols

Alzet osmotic pumps model 1002

Manufactured by Durect
Sourced in United States

ALZET osmotic pumps (model-1002) are laboratory equipment designed to provide continuous and controlled delivery of substances to experimental models. The device uses the principle of osmosis to deliver the substance at a pre-determined rate over an extended period of time.

Automatically generated - may contain errors

4 protocols using alzet osmotic pumps model 1002

1

Genetic and Pharmacological Modulation of Bone Metabolism

Check if the same lab product or an alternative is used in the 5 most similar protocols

Il-1 receptor deficient (Il-1r−/−) mice and Nlrp3 null (Nlrp3−/−) mice were purchased from Jackson Laboratory. All mice were on C57BL6 background, and mouse genotyping was performed by PCR. To induce estrogen deficiency, bilateral ovariectomy (OVX) or sham surgery (in which ovaries were exteriorized, but replaced intact) were performed under general anesthesia in 4-month old WT or Nlrp3−/− mice, and bones were analyzed 8 weeks after surgery. Estrogen deficiency was confirmed by uterine atrophy. For PTH experiments, 80 μg/kg/day human PTH1-34 or vehicle were delivered to 4-month old WT or Nlrp3−/− male mice for 2 weeks via subcutaneously implanted ALZET osmotic pumps (model-1002, DURECT Corporation) with a delivery rate of 0.25 ml/h as previously described46 (link). GST-RANKL or vehicle was administrated intra-peritonally to 3-month old WT or Nlrp3−/− male mice at a dose of 1 µg/kg, daily for 2 days. For pharmacologic inhibition of bone resorption, 40 mg/kg zoledronate (Novartis #484188) were injected subcutaneously to 3-month old WT mice, once a week, for 4 weeks prior to GST-RANKL injection. All procedures were approved by the Institutional Animal Care and Use Committee of Washington University School of Medicine in St. Louis. All experiments were performed in accordance with the relevant guidelines and regulations described in the IACUC-approved protocol #20160245.
+ Open protocol
+ Expand
2

Intraventricular Infusion of Human HCNP

Check if the same lab product or an alternative is used in the 5 most similar protocols
We chemically synthesized human HCNP (PVDLSKWSGPL). Under anesthesia with 1% isoflurane, a midsagittal incision was made on the scalp, and a subcutaneous tunnel was opened between the shoulder blades, where the Alzet osmotic pumps (model 1002; pumping rate 0.25 μL/h, DURECT Corporation, Cupertino, CA, USA) were implanted. Subsequently, a craniotomy at 0.6 mm posterior and 1.2 mm lateral from the bregma was performed stereotactically. The tip of the pump was carefully inserted into the craniotomy site and was angled at 8°. The cannula was fixed in place using dental cement. The incision was closed with silk sutures and dabbed with Vetbond (3M, St Paul, MN, USA). Intraventricular infusion of the vehicle (bicarbonate buffer) or 0.75 pg/h of HCNP was then performed for 14 d.
+ Open protocol
+ Expand
3

Plerixafor Therapy in EAE Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Alzet Osmotic Pumps (Model 1002; Durect Corporation, Cupertino, CA) were
implanted s.c. near the spine of C57/Bl6 mice under sterile conditions at day 8
after induction of EAE. The pumps were filled with Plerixafor®(IBL International, Hamburg, Germany) to allow a constant release of 4
mg/kg/day. Mice of the control groups were sham operated since preliminary tests
had revealed that implantation of osmotic pumps with PBS did not interfere with
EAE.
+ Open protocol
+ Expand
4

Angiotensin II-Induced Hypertension: p38 MAPK Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols
In this study, hypertension was induced in all treatment groups via osmotic minipumps (ALZET Osmotic Pumps, model 1002, DURECT Corporation, Cupertino, CA, USA) with Ang II 1000 ng/min per kg of body weight (BW). Treatment and observation time continued throughout 14 days. Mice were divided into two groups prior to insertion of the minipumps, to either treat with the orally available p38 MAPK inhibitor BIRB796 at a dose of 50 mg/kgBW/d (a generous gift of Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany) or vehicle (the mouse chow, thus oral application) as adopted from previous methods.19 (link) Treatment started 2 days prior to insertion of the osmotic minipumps and lasted throughout an observation time of 14 days.
For the isolated perfused kidney experiments, mice given a saline infusion only served as the untreated controls.
Treatment groups for chronic p38 MAPK inhibition with BIRB796 were as follows:
For the ex-vivo inhibition of p38 MAPK (SB203580) in the isolated perfused kidney and thoracic aortic rings experiments, mice were either infused with saline or with Ang II (1000 ng/kg/min) for 14 days.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!